Naperiglipron
Naperiglipron (LY3549492) (Example 2) is a Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC50 of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC50: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research[1].
Product Specifications
CAS Number
2572566-11-9
Product Name Alternative
LY3549492
UNSPSC
12352005
Target
GLP Receptor; Phosphodiesterase (PDE)
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Concentration
10mM
Purity
99.43
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
FC(C=C(C=C1)C#N)=C1COC2=NC(C(C(C)=C3)=CC(F)=C3CC4=NC5=CC=C(C(O)=O)C=C5N4C[C@H]6OCC6)=CC=C2
Molecular Formula
C33H26F2N4O4
Molecular Weight
580.58
References & Citations
[1]Coates D A, et al. Glucagon-like peptide 1 receptor agonists. WO2020263695A1. 2020-12-30.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDE10
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin 8 (KRT8/803), CF594 conjugate, 0.1mg/mL
1-(3,4-Dichlorophenyl)cyclobutanecarbonitrile
